glp 1 agonist conversion chart Changes in weight with GLP-1 RAs in head-to-head clinical studies. *p < Switching between GLP‐1 receptor agonists
Description
N Engl J Med 384(12):11131124 Osaka T, Endo M, Yamakawa M, Inoue S (2005) Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system

The potential for even greater market volumes exists if ongoing clinical trials confirm the positive effects of GLP-1 agonists on cardiovascular diseases and other conditions like sleep apnea

3337 In individuals with HFrEF, GLP-1 RAs do not affect LV systolic function, whereas the effects of GLP-1 RAs in individuals with HFpEF have not yet been investigated

Reference Lee WT et al

It depends on the concentration
Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide
